Evidence map›Paper›PMID 32939755›Full record

Trial reportClinical and experimental immunology2021

Association of the polymorphism of the Toll-like receptor (TLR)-3 and TLR-9 genes with hepatitis C virus-specific cell-mediated immunity outcomes among Egyptian health-care workers.

S F Abdelwahab, S Hamdy, A M Osman, Z A Zakaria, I Galal, M Sobhy, M Hashem, W R Allam, M Abdel-Samiee, E Rewisha and 1 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

S F AbdelwahabThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.ORCID 0000-0002-9636-7485
S HamdyThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
A M OsmanDepartment of Zoology, Faculty of Science, Cairo University, Giza, Egypt.
Z A ZakariaThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
I GalalThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
M SobhyThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
M HashemThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
W R AllamThe Egyptian Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
M Abdel-SamieeDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia, Egypt.
E RewishaDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia, Egypt.
I WakedDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Menoufia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll-like receptor gene (TLR)-3 is an innate detector of dsRNA viruses, and the TLR-9 gene recognizes bacterial and viral unmethylated cytosine-phosphate-guanosine (CpG) motifs. We previously reported that the TLR-3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR-9 gene played no major role in this infection. This study identified the role of TLR-3.rs3775290 (c.1377C/T), TLR-9.rs5743836 (-1237T→C) and TLR-9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV-specific cell-mediated immunity (CMI) among Egyptian health-care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative-aviraemic HCWs; group 2: 20 seronegative-viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the TLR-3.rs3775290, TLR-9.rs5743836 and TLR-9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV-specific CMI in the four groups using an interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI-responding subjects with different HCV states and TLR-3.rs3775290 or TLR-9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV-specific CMI and the TLR-9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR-9.rs5743836 SNP, but not TLR-3.rs3775290 or TLR-9.rs352140 genotypes, could predict the outcome of HCV-specific CMI responses among Egyptians infected with genotype-4.

Indexed as

Health PersonnelHepacivirusHepatitis C, ChronicImmunity, CellularPolymorphism, Single NucleotideToll-Like Receptor 3AdultFemaleHumansMaleMiddle AgedToll-Like Receptor 9TLR3 protein, humanTLR9 protein, humanToll-Like Receptor 3Toll-Like Receptor 9cell-mediated immunityCMIHCVhealth-care workersSNPTLR-3TLR-9

Identifiers

PMID32939755
PMCPMC7744502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.